Please note, this OEL/ADE monograph also applies to buserelin acetate (CAS RN 68630-75-1). Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland gonadotrophin-releasing hormone (GnRH) receptor (GnRHR). Buserelin is used for the suppression of testosterone in the treatment of malignant neoplasms of the prostate. It is also used in the treatment of endometriosis and as an adjunct to ovulation induction with gonadotrophins in the treatment of infertility. It has been used in central precocious puberty and tried in the treatment of uterine fibroids. Buserelin may be also used in the treatment of hormoneresponsive breast cancers.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Buserelin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.